Re: Cathrine Alvær Vinje, Maria Nyre Vigmostad, Svein R. Kjosavik, Henrik Grönberg, Bjørnar Gilje, Svein Skeie. Prostate Biopsies Can Be Omitted in Most Patients with a Positive Stockholm3 Test and Negative Prostate Magnetic Resonance Imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009
-
Published:2024-03
Issue:2
Volume:10
Page:244-245
-
ISSN:2405-4569
-
Container-title:European Urology Focus
-
language:en
-
Short-container-title:European Urology Focus
Author:
Liu Wujianhong,
He Yanyan,
Yang BinORCID
Reference5 articles.
1. Alvær Vinje C, Nyre Vigmostad M, Kjosavik SR, Grönberg H, Gilje B, Skeie S. Prostate biopsies can be omitted in most patients with a positive Stockholm3 test and negative prostate magnetic resonance imaging. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.08.009.
2. MRI-targeted or standard biopsy in prostate cancer screening;Eklund;N Engl J Med,2021
3. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients;Boyle;Eur J Cancer,2019
4. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial;Nordström;Lancet Oncol,2021
5. External validation of the Rotterdam prostate cancer risk calculator and comparison with Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort;Palsdottir;Eur Urol Focus,2023